Releases limited quantities of Cilamin 250 capsules in retail market
Panacea Biotec announced that the Company's brand Cilamin 250 capsules for treatment of Wilsons disease, Rheumatoid Arthritis and other conditions has been made available in limited quantities in the retail market.The temporary shortage is due to sudden disruption of supplies of raw materials by qualified supplier beyond the control of the Company. Due to continuous efforts the Company has resumed limited production of Cilamin 250 and has released limited quantities in the market from 29 September 2016.
The Company expects it would take additional 2-4 weeks for accessing the additional quantities of raw material and additional 4 weeks for Cilamin 250 supplies to normalise.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
